Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antiphospholipid Syndrome | 5 | 2023 | 37 | 2.280 |
Why?
|
| Antibodies, Antiphospholipid | 5 | 2024 | 29 | 1.960 |
Why?
|
| Mastocytosis | 3 | 2025 | 14 | 1.630 |
Why?
|
| Primary Dysautonomias | 2 | 2024 | 4 | 1.460 |
Why?
|
| Immunoglobulins, Intravenous | 4 | 2019 | 133 | 1.350 |
Why?
|
| Migraine Disorders | 2 | 2023 | 113 | 1.240 |
Why?
|
| Postural Orthostatic Tachycardia Syndrome | 3 | 2022 | 11 | 1.100 |
Why?
|
| Mast Cells | 2 | 2025 | 148 | 0.840 |
Why?
|
| Immunoglobulin M | 1 | 2024 | 281 | 0.760 |
Why?
|
| Pyridones | 2 | 2021 | 201 | 0.690 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2023 | 238 | 0.630 |
Why?
|
| Autonomic Nervous System Diseases | 2 | 2017 | 36 | 0.620 |
Why?
|
| Polyradiculoneuropathy | 1 | 2019 | 5 | 0.590 |
Why?
|
| Pyrazoles | 2 | 2021 | 512 | 0.590 |
Why?
|
| Autoimmune Diseases of the Nervous System | 1 | 2019 | 31 | 0.590 |
Why?
|
| Excipients | 1 | 2019 | 55 | 0.580 |
Why?
|
| Fibrinolytic Agents | 1 | 2021 | 290 | 0.540 |
Why?
|
| Complex Regional Pain Syndromes | 1 | 2017 | 3 | 0.510 |
Why?
|
| Immunologic Factors | 1 | 2019 | 259 | 0.510 |
Why?
|
| Esophageal Motility Disorders | 1 | 2017 | 30 | 0.500 |
Why?
|
| Autonomic Nervous System | 1 | 2017 | 81 | 0.490 |
Why?
|
| Nerve Fibers | 1 | 2017 | 105 | 0.490 |
Why?
|
| Neuralgia | 1 | 2017 | 148 | 0.450 |
Why?
|
| Mixed Connective Tissue Disease | 1 | 2014 | 10 | 0.430 |
Why?
|
| Papillomavirus Vaccines | 1 | 2017 | 295 | 0.400 |
Why?
|
| Immunotherapy | 2 | 2022 | 662 | 0.390 |
Why?
|
| Anticoagulants | 1 | 2017 | 729 | 0.350 |
Why?
|
| Young Adult | 7 | 2025 | 14122 | 0.340 |
Why?
|
| Lymph Nodes | 1 | 2014 | 501 | 0.340 |
Why?
|
| Adolescent | 8 | 2025 | 22409 | 0.290 |
Why?
|
| Middle Aged | 9 | 2025 | 35971 | 0.270 |
Why?
|
| Retrospective Studies | 6 | 2024 | 17149 | 0.220 |
Why?
|
| Adult | 8 | 2025 | 40489 | 0.200 |
Why?
|
| Humans | 17 | 2025 | 144671 | 0.200 |
Why?
|
| Female | 11 | 2025 | 78304 | 0.200 |
Why?
|
| Hypertrichosis | 1 | 2023 | 9 | 0.190 |
Why?
|
| Acromegaly | 1 | 2023 | 17 | 0.190 |
Why?
|
| Limb Deformities, Congenital | 1 | 2023 | 22 | 0.190 |
Why?
|
| Hypertension, Pulmonary | 1 | 2014 | 1948 | 0.190 |
Why?
|
| Headache | 1 | 2023 | 151 | 0.170 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2021 | 82 | 0.160 |
Why?
|
| Male | 9 | 2025 | 72431 | 0.160 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 1 | 2021 | 71 | 0.160 |
Why?
|
| Child | 6 | 2021 | 22600 | 0.160 |
Why?
|
| Minors | 1 | 2020 | 14 | 0.150 |
Why?
|
| Academic Success | 1 | 2020 | 30 | 0.150 |
Why?
|
| Child Protective Services | 1 | 2020 | 65 | 0.150 |
Why?
|
| Immunization, Passive | 1 | 2019 | 88 | 0.140 |
Why?
|
| Aspirin | 1 | 2021 | 402 | 0.130 |
Why?
|
| Sweat Glands | 1 | 2017 | 5 | 0.130 |
Why?
|
| Aged | 4 | 2025 | 25955 | 0.130 |
Why?
|
| Hemorrhage | 1 | 2021 | 813 | 0.110 |
Why?
|
| Myeloproliferative Disorders | 1 | 1995 | 20 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2019 | 2019 | 0.110 |
Why?
|
| Treatment Outcome | 2 | 2021 | 11735 | 0.110 |
Why?
|
| Rivaroxaban | 1 | 2017 | 268 | 0.110 |
Why?
|
| Interferon Type I | 1 | 1994 | 146 | 0.100 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 1994 | 127 | 0.100 |
Why?
|
| Severity of Illness Index | 1 | 2021 | 2922 | 0.090 |
Why?
|
| Stroke | 1 | 2021 | 1262 | 0.090 |
Why?
|
| Pregnancy | 1 | 2024 | 7122 | 0.080 |
Why?
|
| Autoimmunity | 1 | 2017 | 930 | 0.080 |
Why?
|
| Prospective Studies | 1 | 2017 | 7994 | 0.050 |
Why?
|
| Plasmapheresis | 1 | 2022 | 24 | 0.050 |
Why?
|
| Immunoglobulins | 1 | 2022 | 160 | 0.040 |
Why?
|
| New South Wales | 1 | 2020 | 22 | 0.040 |
Why?
|
| Mathematics | 1 | 2020 | 100 | 0.040 |
Why?
|
| Information Storage and Retrieval | 1 | 2020 | 122 | 0.040 |
Why?
|
| Reading | 1 | 2020 | 135 | 0.040 |
Why?
|
| Schools | 1 | 2020 | 450 | 0.030 |
Why?
|
| Splenomegaly | 1 | 1995 | 15 | 0.030 |
Why?
|
| Lymphatic Diseases | 1 | 1995 | 21 | 0.030 |
Why?
|
| Blood Cell Count | 1 | 1995 | 55 | 0.030 |
Why?
|
| Remission Induction | 1 | 1994 | 309 | 0.030 |
Why?
|
| Drug Costs | 1 | 1994 | 117 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 1994 | 1363 | 0.020 |
Why?
|
| Survival Rate | 1 | 1994 | 2089 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 1994 | 5414 | 0.010 |
Why?
|